HOME >> BIOLOGY >> NEWS
Anti-cholesterol drug treats Alzheimer's disease in mice

ficant cognitive benefit for AD patients with normal serum cholesterol."

Although CP-113,818 has not been tested in clinical trials, another ACAT inhibitor, avasimibe, developed by Pfizer, is now in final clinical trials as a treatment for vascular disease and atherosclerosis. That drug is "considered safe for human use, with a good therapeutic window," wrote Kovacs and her colleagues.

"Our results suggest that slow-release biopolymer administration of ACAT inhibitors may be considered as a potential strategy for the treatment and prevention of Alzheimer's disease, alone or in combination with statins," they wrote.

Birgit Hutter-Paier, Henri J. Huttunen, Luigi Puglielli, Christopher B. Eckman, Doo Yeon Kim, Alexander Hofmeister, Robert D. Moir, Sarah B. Domnitz, Matthew P. Frosch, Manfred Windisch, and Dora M. Kovacs: "The ACAT Inhibitor CP-113,818 Markedly Reduces Amyloid Pathology in a Mouse Model of Alzheimer's Disease"


'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
13-Oct-2004


Page: 1 2

Related biology news :

1. Stem cell procedure successfully treats amyloidosis patients
2. New compound effectively treats fungal infections
3. Antibiotic treats lymphoma of the eye
4. Gene therapy advance treats hemophilia in mouse models
5. Device creates electricity and treats wastewater
6. Antarctic ice shelf retreats happened before
7. Gilbert Foundation and American Fed for Aging Research award grants on Alzheimers disease
8. Link identified between Alzheimers disease and glaucoma
9. UCF research links proteins, stem cells and potential Alzheimers treatment
10. Journal of Alzheimers Disease achieves significant impact factor
11. Alzheimers prevention role discovered for prions

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... -- Symic Bio, a biopharmaceutical company focused on matrix ... announced today the completion of enrollment for the SHIELD ... trial will evaluate the safety and efficacy of SB-030, ... restenosis following angioplasty. "We,re pleased to ... Nathan Bachtell , M.D., Chief Medical Officer of ...
(Date:2/24/2017)... ... , ... FireflySci, Inc is an explosive small business that continues to grow ... bringing their powerful cuvette and spectrophotometer calibration to the spectroscopy world. ... on as they add yet another mark on the global map. , With distributors ...
(Date:2/24/2017)... 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a ... Key Opinion Leader event to highlight new clinical data ... presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and ... be held in-person and via live webcast on Tuesday, ... PST at the Lotte New York Palace Hotel in ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... portfolio to include an array of biochemical analyses critical for Lead Discovery. ... drive their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of ...
Breaking Biology Technology:
Cached News: